Search our team at AdventHealth Research Institute
-
NCT05901831
FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes
This study is not currently enrolling.Research Area: Translational ResearchResearch Location: Orlando, FloridaStudy Purpose: The aim of the study is to demonstrate efficacy of Finerenone when compared to placebo, in addition to standard of care, in delaying the progression of chronic kidney disease (CKD) in...
-
NCT05891171
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchObjectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
-
NCT06122961
POSEIDON – Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Tampa, FloridaWe are doing this study to collect information about the number of people with cardiovascular disease who have high levels of inflammation throughout the body. Cardiovascular disease is a general name...
-
NCT05904886
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)
This study is not currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this...
-
NCT06253130
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
-
NCT04717414
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking...
-
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect... -
NCT05685004
Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchThis clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and...
-
NCT05757869
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
This study is not currently enrolling.Research Area: Heart, Lung and Vascular ResearchResearch Location: Tampa, FloridaThe purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke...
-
NCT04083599
GCT1042-01: A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaGEN1042 is a bispecific antibody that crosslinks CD40 on antigen-presenting cells with 4-1BB on activated T cells, thereby inducing conditional stimulation of and co-stimulatory activity on both cell...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...
-
NCT05629585
D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaWe are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug...